GB1908 

GB1908 is a selective and orally active galectin-1 inhibitor with K_i values of 57 nM and 72 nM for human and mouse galectin-1, respectively. GB1908 displays >50-fold selectivity over galectin-3. GB1908 can be used for the study of lung cancer^[1].

GB1908 (0.1-10 μM; 16 h) inhibits galectin-1-induced apoptosis in Jurkat cells (IC₅₀ of 850 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GB1908 (compound 5d; 30 mg/kg; po; twice a day; for 21 days) reduces the growth of primary lung tumor LL/2 in a syngeneic mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

505.40

C₁₈H₁₈Cl₂N₄O₅S₂

ClC1=CC(S[C@H]2O[C@H](CO)[C@H](O)[C@H](N3C=C(C4=CSC(O)=N4)N=N3)[C@H]2OC)=CC=C1Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fredrik R Zetterberg, et al. Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer. J Med Chem. 2024 May 28.  [Content Brief]